Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 50Pancreatic Neoplasms 14Neoplasms 11Lung Neoplasms 11Neoplasm Metastasis 7Breast Neoplasms 6Brain Neoplasms 6Head and Neck Neoplasms 4Gliosarcoma 4Glioblastoma 4Carcinoma, Hepatocellular 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Neuroendocrine Tumors 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Prostatic Neoplasms 2Oligodendroglioma 2Non-Squamous Non-Small Cell Lung Cancer 2Glioma 2Familial ependymoma 2Esophageal Neoplasms 2Ependymoma 2Carcinoma, Renal Cell 2Carcinoma 2Carcinoid Tumor 2Astrocytoma 2Urinary Bladder Neoplasms 1Thrombocytosis 1Thoracic Neoplasms 1

Interventions

Carboplatin 3etoposide phosphate 2Topotecan 2Ifosfamide 2Filgrastim 2Etoposide 2Erlotinib Hydrochloride 2Cyclophosphamide 2transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1sodium thiosulfate 1sargramostim 1Thiotepa 1Stem Cell Transplantation 1Semaxinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Microarray Analysis 1Mesna 1Melphalan 1Mannitol 1Immunohistochemistry 1Granulocyte Colony-Stimulating Factor 1Dexamethasone 1Dasatinib 1Cyproheptadine 1Calcium Dobesilate 1Busulfan 1Blotting, Western 1Acetylcysteine 13-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Familial ependymoma × Erlotinib Hydrochloride × Clear all
NCT01032070 2024-12-12

PETEY

Astellas Pharma Inc

Phase 2 Terminated
25 enrolled 23 charts

Familial ependymoma, Ependymoma, Recurrence

NCT01247922 2024-12-06

Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205

Astellas Pharma Inc

Phase 2 Terminated
4 enrolled 9 charts

Familial ependymoma, Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡